Myovant Sciences, a biotech developing therapies for women's health diseases and other endocrine-related disorders, filed on Friday with the SEC to raise up to $173 million in an initial public offering.
The Hamilton, Bermuda-based company was founded in 2016 and booked n/a in sales for the 12 months ended . It plans to list on the NYSE under the symbol MYOV. Citi, Cowen & Company, Evercore ISI and Barclays are the joint bookrunners on the deal. No pricing terms were disclosed.
